
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings Corp has demonstrated impressive financial growth, achieving a remarkable 65% year-over-year increase in core exome/genome revenue for Q3, resulting in both topline and bottom-line performance surpassing expectations. The company has also raised its 2025 revenue guidance to $425-428 million, reflecting a solid annual growth projection of 39%-40%, supported by a significant increase in average selling prices to $3,850 per test, up 23% year-over-year. Additionally, the strategic realignment to target pediatric neurologists and the expansion of its offerings to over 30 biopharma programs in rare diseases further enhance GeneDx's market position and long-term growth potential.
Bears say
GeneDx Holdings Corp is projected to experience a significant cash burn of approximately $2 million per quarter, raising concerns about its financial sustainability. The company faces a critical risk related to third-party payer reimbursement, as inadequate payment structures or renegotiations could hinder commercial success, exacerbated by a high denial rate of 45% for tests despite being contracted with around 80% of health plans. Additionally, the reliance on a limited number of sales representatives and the potential disruptions in data and workflow services further contribute to the negative outlook regarding the company's operational effectiveness and financial health.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares